OS Therapies Reaches Major Milestone in Osteosarcoma Phase 2b Clinical Trial

Company marches another step closer to delivering the first new treatment for osteosarcoma in 40 years

OS Therapies (NYSE-A: OSTX), a leading biopharmaceutical company specializing in ADC and immunotherapy research, has announced a major milestone in its AOST-2121 clinical trial (NCT04974008) for OST-HER2. The trial, which targets recurred, resected osteosarcoma, has completed its final treatment dose for the last enrolled patient, marking the end of the treatment phase.

OST-HER2 is an innovative immunotherapeutic vaccine using a Listeria monocytogenes (Lm) vector, designed to prevent metastasis, delay recurrence, and increase survival in osteosarcoma patients. The trial involved 41 patients across 21 clinical sites in the U.S., with a focus on 12-month Event Free Survival (EFS) and 36-month Overall Survival (OS).

With the completion of the final patient’s treatment, OS Therapies is preparing to close all clinical sites, lock the database, and begin data analysis. Topline data, including EFS and interim 2-year OS results, are expected in Q4 2024.

Share this article:

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Share this article:
Read Full Disclaimer

Share This Article

 

About the Author

OS Therapies Reaches Major Milestone in Osteosarcoma Phase 2b Clinical Trial

Ashlee Vogenthaler

Markets Editor